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ABSTRACT Since there are no standardized protocols regarding the detec-
tion of microscopic melanoma deposits in sentinel lymph nodes (SLN), the 
aim of this study was to present our experience with intraoperative cytologi-
cal evaluation of SLN in patients with melanoma. The study included 475 
SLN biopsies (SLNB) from 201 patients with primary cutaneous melanoma 
of intermediate thickness. Each lymph node was cut in half; touch imprint 
cytology (TIC) preparations of all cut surfaces were performed and stained 
according to a modified May-Grünwald-Giemsa method. The results were 
compared to definitive postoperative histology. Twenty of 25 SLNB positive 
on TIC proved to be metastatic when compared to definitive histology. Most 
of 32 SLN that were suspicious but not diagnostic on TIC were proven nega-
tive (23/32, 71.8%), while 7 nodes had metastases (one micrometastasis and 
one with isolated tumor cells only). The majority (94%) of SLNBs negative on 
TIC remained negative on final histology, while 6% or 25 nodes were positive, 
mostly with micrometastases or isolated tumor cells (17/25). In frozen sec-
tions performed in cases of suspicious or positive SLN cytology, metastasis 
was confirmed in 80% of positive and in 21.9% of suspicious TIC. Altogether, 
49% (27/55) of positive SLNB were identified intraoperatively in 57% (24/42) 
of patients, and in those cases a complete regional lymph node dissection 
was performed in the first step. TIC assessment of SLNB with 99% specific-
ity and 57% sensitivity for intraoperative identification of metastasis is useful 
and beneficial for avoiding a second operative procedure.
KEY WORDS: sentinel lymph node biopsy, touch imprint cytology, melano-
ma, intraoperative
INTRODUCTION
Melanoma accounts for only 4% of all malignant 
neoplasms, but it is responsible for more than 77% 
of skin cancer deaths (1). According to the American 
Joint Committee on Cancer (AJCC) (2009), metasta-
ses to regional lymph nodes are the most important 
prognostic factor in patients with early-stage mela-
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noma (2). Sentinel lymph node biopsy (SLNB) for pa-
tients with primary cutaneous melanoma was first 
introduced in the early 1992 (3) and since then it has 
been established as a reliable indicator of the pres-
ence of micrometastases in the nodal basin and an 
accurate prognostic factor in primary melanoma (4). 
The concept of SLNB is based on the principle that 
all lymphatic fluid from a certain body part is drained 
to regional lymph nodes. The first of nodes draining 
a specific site (thus named “sentinel node”), can be 
detected, removed, and evaluated for the presence 
of malignant cells. Intraoperative SLNB examination 
has been demonstrated to be accurate staging pro-
cedure in patients with melanoma that helps avoid 
complete regional lymph node dissection in patients 
with clinically negative nodes (5-11). For this reason, 
an elaborate histopathologic assessment of the SLN 
that drains primary cutaneous melanoma is essential 
for an individualized prediction of clinical outcome, 
and for recognizing the need for immediate com-
plete regional lymph node dissection (CLND). Despite 
the use of intraoperative SLNB for more than 16 years, 
there is still no consensus on the “correct” way to sam-
ple the SLN (12,13). 
SLNB was developed using intraoperative frozen 
sections because CLND could be performed immedi-
ately if the SLN contained tumor cells. When an SLNB 
sample is prepared for frozen section analysis, part of 
the lymph node is sacrificed until a reliable cut sur-
face is obtained. This loss of tissue may lead to false 
negative results in small lymph node metastases. This 
could be the reason for discouraging the use of fro-
zen section analysis of SLN.
The aim of the present study was to report our 
experience in handling SLNB in patients with cutane-
ous melanoma of Breslow thickness >1 mm and <4 
mm, with a special goal of comparing the results of 
intraoperative cytological evaluation of nodal cut 
surfaces with histological analysis. Since a standard 
protocol for intraoperative detection of microscopic 
melanoma deposits in SLNB is still lacking according 
to literature data, the aim was to present our expe-
rience and to discuss and compare our results with 
literature data.
PATIENTS AND METHODS
Patients and operative procedure 
Between 2006 and 2014, 201 consecutive patients 
diagnosed with cutaneous melanoma of Breslow 
thickness >1 mm and <4 mm undergoing surgery at 
University Department of Surgery, Rijeka University 
Hospital Centre for SLN biopsies were included in the 
study. Patients gave oral informed consent. The study 
was performed with the approval of Ethics Commit-
tee of Clinical Hospital Center Rijeka and the Faculty 
of Medicine, University of Rijeka. Sentinel lymph node 
detection was performed with 99mTc labelled human 
serum albumin colloid (Nanocoll*, GE Healthcare, 
Italy), with 95% of particles with a diameter ≤80 nm. 
Four injections surrounding the scar after initial sur-
gical procedure for melanomas located on the trunk 
and two injections for the lesions located on the ex-
tremities were applied intradermally within 1 cm of 
lesion margins. Total activity administered was 30-40 
MBq, split into 2 or 4 aliquots of 0.1-0.2 mL volume 
per aliquot, each followed with 0.2 mL air bubble. 
Imaging was performed with a two-headed 
gamma camera (Siemens E-CAM or Siemens Sym-
bia T, Germany) immediately after the application of 
the radiopharmaceutical, starting with 20 minutes 
of dynamic acquisition over the region of interest 
(matrix 128×128, 20 frames, 60 s/frame). Then, static 
acquisitions of the same region in different projec-
tions were performed depending on the localization 
of the lesion (matrix 256×256, 300 s per projection). 
Single photon emission computerized tomography 
(SPECT, matrix 64×64, 32 views, 30s/view, detectors, 
non-circular orbit, step and shoot) and additional hy-
brid SPECT/CT imaging (SPECT combined with “low 
dose” CT) was performed when appropriate, usually 
in melanoma of the trunk, in difficult locations (“in 
transit” nodes), or equivocal situations. “Low dose” CT 
imaging started immediately after completed SPECT 
acquisition, following determination of cranial and 
caudal limits of the scanned region in the CT protocol 
(30 mA, 130 kV, slice 5 mm, Acq 2×2.5 mm, PITCH: 1.5). 
After the CT session, reconstructions were performed 
with specific software applications (B08s SPECT AC; 
B30s; B70s).
The imaging ended with whole body planar scan-
ning in anterior and posterior projections at a scan 
speed of 18 cm/min. Focal, persistent activity in the 
regional lymph node basin with associated lymphatic 
path leading from the injection site was considered 
the first draining node and defined as a sentinel 
lymph node (SLN). It was marked on the skin with a 
water resistant pen and on the image as SLN. When 
more than one lymph node was visualized, they were 
marked on the skin and on the image with numbers 
assigned according to the order of appearance. If 
more than one region contained lymph node activity, 
the first node (SLN) was marked in each basin.
The patients were then transferred to the operat-
ing room, where the radioactive SLN (or SLNs) was 
detected with a hand-held gamma probe (Neoprobe 
2000, Ireland). The signal was considered significant 
when the number of counts detected in the node 
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exceeded ten times the background activity of the 
body. After the removal of the suspected SLN, the 
activity in the removed nodes was confirmed with a 
gamma probe, as well as residual (diminished) activ-
ity in the extraction site. In cases where the remaining 
activity was still present in the operating field, further 
nodes were searched for and removed. The extracted 
nodes were sent for intraoperative analysis.
Sentinel lymph node examination 
A total of 475 SLNB from 201 patients with pri-
mary cutaneous melanoma were assessed. Depend-
ing on the node size, each node was longitudinally 
cut into 2-3 mm sections. Care was taken to obtain 
complete cross sections of the maximum diameter, 
preferably including the hilum and the marginal si-
nus. For each lymph node half, a pair of imprints were 
made by gently touching the cut surface of the SLNB 
to glass slides that were subsequently processed with 
modified May-Grünwald-Giemsa staining. Touch im-
print cytology (TIC) of every section was assessed in-
traoperatively by two cytologists. Diagnostic catego-
ries included positive, negative, and suspicious but 
not diagnostic findings. Suspicious TIC results were 
considered negative. In case of a negative cytology 
report, the node was fixed in neutral buffered forma-
lin and embedded in paraffin, according to standard 
procedures (Table 1). In case of positive or suspicious 
cytological findings, the selected sections were fro-
zen and 5 serial sections (6 μm thick) were taken. The 
sections were immediately fixed with cold acetone 
for 2-3 minutes and then stained. Positive histological 
results prompted CLND. 
Lymphadenectomy completion was at the sur-
geon’s discretion when only the TIC result was posi-
tive and the frozen section negative. After intraopera-
tive interpretation, the SLNB sample was fixed in 10% 
buffered formalin, processed in the usual manner, and 
embedded in paraffin. For each SLN, an initial section 
was cut and stained with hematoxylin-eosin (HE). Fol-
lowing histopathologic examination, the SLNB that 
were initially negative for tumor on HE were further 
examined according to the accepted protocol (14-
16). The pathologist recorded the extent, size, and 
extracapsular extension of the tumor. For statistical 
purposes, the metastases were classified according 
to the largest nodal tumor deposit as a metastasis (>2 
mm), micrometastasis (>0.2 to <2 mm), and isolated 
tumor cells (<0.2 mm). TIC results were compared 
with definitive postoperative histopathology results. 
Statistics 
Sensitivity was defined as the percentage of posi-
tive TIC results among those with a positive definitive 
histology. Suspicious TIC results were considered neg-
ative in statistical analysis. Specificity was defined as 
the percentage of negative TIC results among those 
with a negative definitive histology. The false-nega-
tive rate was defined as the number of false-negative 
intraoperative TIC results divided by the sum of false 
negative and false-positive results. For the purpose of 
this study, the level of statistical significance was set 
at P<0.05.
 RESULTS
The study cohort comprised 201 patients with cu-
taneous melanoma whose 475 SLNB were analyzed. 
The mean number of analyzed lymph nodes per pa-
tient was 2.4 (range, 1 to 7). Patient age ranged from 
30 to 88, mean age 59 years. There were 94 (45%) 
female and 114 (55%) male patients. Out of 201 pa-
tients undergoing SLNB analysis, positive nodes were 
found in 42 (20%) patients.
TIC was performed intraoperatively on all 475 
SLNB and the results were compared with the final 
histology findings. Of 475 TIC specimens, 418 (88%) 
were negative, 32 (6.7%) suspicious but not diagnos-
tic, and 25 (5.3%) were positive, while the correspond-
ing distribution of histopathologic diagnosis was 420 
(88.5%) negative and 55 (11.5%) positive. Of 55 posi-
tive SLNB on final histological analysis, 35 (64%) were 
metastases (>2 mm), 16 (29%) micrometastases (0.2-
2 mm), and 4 (7%) isolated tumor cells (<0.2 mm).
The concordance of TIC and final histology results 
is summarized in Table 2. Out of 25 SLNB positive on 
TIC, 20 (80%) proved to be metastases and one to be 
a micrometastasis on final histology as compared 
with definitive histology. Four out of 25 SLN were 
proven negative on final histology. Most of 32 SLNB 
that were suspicious but not diagnostic on TIC, were 
negative on definite histology (n=23, 72%), while 7 
Table 1. Sentinel lymph node biopsy (SLNB) in-
traoperative evaluation with a decision on further 
steps using the the cutaneous melanoma protocol 
for SLNB
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(22%) had metastases, one micrometastasis, and one 
isolated tumor cells. SLN that were negative on TIC 
were confirmed to be negative on final histology in 
94% (393/418) of cases, while 6% (25/418) were posi-
tive, mostly presenting as micrometastases and iso-
lated tumor cells (17/25). 
Only one of 16 cases with micrometastases was 
positive and another one was suspicious on TIC. Fi-
nally, TIC yielded a suspicious result in only one of 4 
SLNB with isolated tumor cells. 
Intraoperative TIC identified positive SLNB in 4 
(16%) cases, while metastases were not detected on 
HE and immunohistochemistry.  
Simultaneous frozen section analysis was indicat-
ed in 57 cases with positive and suspicious TIC results. 
Concordance between intraoperative TIC and frozen 
section in cases of suspicious or positive SLNB cytol-
ogy is shown in Table 3. In frozen sections, metas-
tases were confirmed in 20/25 (80.0%) positive and 
7/32 (21.9%) suspicious TIC. Altogether, 27/55 (49.0%) 
positive SLNB were identified intraoperatively. 
However, the number of positive SLNB increased 
to 31/55 (56.3%) on final examination. More precise-
ly, 1 SLNB from the group of positive TIC (metastasis 
greater than 2 mm) and another 3 from suspicious 
TIC, but negative on frozen section, were positive on 
final histology (two micrometastases and one isolated 
tumor cells). However, the majority of suspicious TIC 
findings (72%) were negative on final analysis. During 
surgery, suspicious but not diagnostic TIC results were 
considered negative. Thus, CLND was performed in 
the first step in 18 (43%) of 42 SLNB positive cases. 
The accuracy of intraoperative TIC according to 
the size of tumor infiltration in SLNB is shown in Table 










Metastasis (>2 mm) 20 (80.0%) 7 (22.0%) 8 (1.9%)
Micrometastasis (<2 mm) 1 (4.0%) 1 (3.0%) 14 (3.3%)
Isolated tumor cells 0 (-) 1 (3.0%) 3 (0.7%)
Negative 4 (16.0%) 23 (72.0%) 393 (94.0%)
Total 25 32 418
Frozen section Final histology
TIC Total Positive Negative Positive Negative
Positive 25 (47.5%) 20 (80.0%) 5 (20.0%) 21 (84.0%) 4 (16.0%)
Suspect 32 (52.5%) 7 (21.9%) 25 (78.1%) 10 (31.2%) 22 (68.7%)
Table 3. Concordance between intraoperative touch imprint cytology (TIC) and frozen section in cases of 
suspect or positive cytology (N=57)
4. Specificity was 99%, while sensitivity was lower, 
i.e. 38%. However, the sensitivity increased to 57% in 
cases with lymph node tumor cell infiltration greater 
than 2 mm. 
DISCUSSION
It is well accepted that lymph node status is an 
important prognostic indicator in patients with cu-
taneous melanoma. Since lymph node dissection is 
associated with significant morbidity and SLN proved 
representative of the remaining nodal basin status, 
the SLNB technique has been increasingly used.
SLNB was developed using intraoperative frozen 
sections because CLND could be performed immedi-
ately rather than later if the SLN contained a tumor, 
thus obviating the need for two surgical procedures 
(17,18). However, experience has shown that frozen 
sections are not reliable enough and the whole proce-
dure is associated with several problems. Preparation 
of a full-face frozen section often requires discarding 
a substantial amount of nodal tissue during frozen 
block cutting. Thus, there is often a significant tissue 
loss, potentially interfering with subsequent more 
detailed pathological examination of paraffin-em-
bedded specimens. The procedure is time-consum-
ing, and some artefacts may be introduced during 
the process of specimen freezing and thawing, thus 
additionally hampering identification of melanoma 
cells, which are generally more difficult to recognize 
in frozen tissue sections than in slides from well-fixed 
tissues. Consequently, some consensus groups have 
discouraged frozen section examination of SLNB. 
According to their opinion, the melanoma-draining 
SLNB should be evaluated as sections from well-
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Specificity Sensitivity PPV NPV
Total* 99% (0.97-0.99) 38,2% (0.25-0.52) 84% (0.64-0.95) 92% (0.89-0.94)
Macrometastasis (>2 mm) 99% (0.97-0.99) 57,1% (0.39-0.74) 83,3% (0.62-0.95) 96,5% (0.94-0.98)
fixed paraffin-embedded tissues (18) or with rapid 
immunohistochemistry for HMB45, S-100, and the 
melanoma cocktail that may help detect melanoma 
cells in SLNB intraoperatively (19). Contrary to “com-
mon knowledge”, performing frozen section analysis 
of SLNB in patients with breast cancer, according to 
some authors, does not impair the probability of de-
tecting lymph node metastases (20).
Generally, frequently reported methods of in-
traoperative assessment are frozen section histol-
ogy and imprint or touch-preparation cytology (14). 
Touch imprint cytology has been demonstrated to be 
a very efficient tool for intraoperative assessment of 
SLNB and, according to literature data, comparable in 
accuracy to frozen sectioning. In our department, TIC 
has been included in the protocol for intraoperative 
analysis of SLNB in association with frozen section in 
case of positive or suspicious TIC. According to the 
results obtained, the specificity of this method was 
99%, while the sensitivity was lower, ranging from 
38% to 57% depending on the size of SLNB metasta-
sis. In a previous report by Messina et al., the specific-
ity and sensitivity of TIC in patients with melanoma 
was 100% and 62%, respectively (21). However, the 
Table 4. Accuracy of intraoperative imprint cytology according to the size of nodal tumor infiltration
results referred to a small number of cases analyzed 
by this technique, i.e. 23 lymph nodes from 13 of 
357 patients. The authors conclude that a thorough 
pathologic evaluation of SLN in patients with mela-
noma requires complete submission of the whole 
tissue, routine use of immunohistochemistry, and TIC 
in selected cases (21). In breast cancer, the positive 
predictive value of intraoperative TIC analysis of SLNB 
for axillary metastasis was 100%, sensitivity was 48%, 
and specificity 100% (22). In lobular carcinoma, where 
the evaluation of SLNB is frequently challenging, the 
sensitivity was 52%, specificity 100%, accuracy 82%, 
and negative predictive value 78% (23).
A relatively high number of suspicious TIC results 
in our study were probably associated with the find-
ings of pigmentophage or cell aggregates that were 
difficult to analyze; thus, most of these cases were 
negative on definitive histology analysis. The similar-
ity between histiocytes and melanocytes in cytologi-
cal smear is well known (Figure 1, A) and therefore 
great effort was invested in some studies to identify 
the best protocol for assessment of SLN using his-
tology, immunohistochemistry, and even RT-PCR 
(15,24). 
Figure 1. A: Imprint preparation of the sentinel lymph node biopsy (SLNB) cut surface (modified May-Gruenwald-Giemsa 
-MGG staining technique, magnification ×200): among numerous lymphocytes, there are many single large melanoma cells 
with large nucleoli, some of them binuclear and with abundant cytoplasm. Cytologic diagnosis on TIC was positive for mela-
noma cells while final histology analysis was negative. B: Imprint preparation of the SLNB cut surface (modified May-Gruen-
wald-Giemsa -MGG staining technique, magnification ×200): a cluster of large cells with large nucleoli, some binuclear cells, 
with abundant cytoplasm and dark pigment in one cell resembling pigmentophages or melanocytes. Cytologic diagnosis on 
TIC was suspicious of melanoma cells while final histopathology was negative.
*All positive lymph nodes regardless of the size of nodal tumor infiltration; PPV: positive predictive value; NPV: negative 
predictive value; 95% confidence interval in parentheses
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In case of “false” positive results, TIC was revised 
and malignant cells were confirmed in all cases (Fig-
ure 1, B). A possible explanation for the likely “false” 
positive TIC could be a very small amount of tumor 
cells or that tumor cells were lost during frozen sec-
tion preparation. On the other hand, the “false” nega-
tive results could probably be explained by the fact 
that only a touch imprint of cut surfaces was analyzed 
intraoperatively, while the tumor cells were probably 
located in a deeper part of the lymph node. Most 
“false” negative results were associated with micro-
metastases (<2 mm) and isolated tumor cells. 
The joint committee of the Society of Surgical 
Oncology and the American Society of Clinical Oncol-
ogy has recently issued an evidence-based guideline 
recommending SLN biopsy in patients with interme-
diate-thickness melanoma and considering the pro-
cedure in patients with thick melanomas. The final 
long-term follow up data from a randomized interna-
tional clinical trial of SLN biopsy versus observation 
reinforces the evidence for the use of SLN biopsy in 
these patients (25). Even in thick (>4 mm) melano-
mas, SLNB is recognized as an important prognostic 
factor for overall survival and disease-free survival 
(26); on the other hand, relatively few patients with 
thin melanomas have positive SLN, thus alternative 
strategies to identify patients at risk of nodal disease 
are needed (27). 
The prognostic significance of small foci of mela-
noma in SLN has been reevaluated over time. Accord-
ing to an Australian report, nearly 20% of patients 
with micrometastases <0.1 mm died from metastatic 
melanoma (28). Moreover, patients with only a single 
metastatic melanoma cell identified in the SLN may 
develop widely disseminated metastatic disease 
(29-31). In the American Joint Committee staging 
scheme, the identification of solitary melanoma cells 
in SLN upstages the patient and leads to a shift in 
clinical management from observation (if the lymph 
node is negative) to CLND and often adjuvant ther-
apy. In contrast, some authors report that CLND did 
not significantly influence disease-specific survival 
in patients with SLN-positive melanoma (32). In ad-
dition, the most recent studies do not recommend 
CLND in patients with melanoma with lymph node 
micrometastases of at least a diameter of 1 mm or 
smaller (33).
Regardless of the clinical significance of SLN mi-
crometastases, there is still interest and progress 
in the development of protocols for the analysis of 
melanoma SLNB. A standardized protocol could have 
many potential benefits, including improvement in 
cross-institution reproducibility of diagnostic and 
clinical trial enrolment criteria. We have accepted 
the protocol for SLNB in melanoma patients, which 
includes intraoperative TIC assessment, since we be-
lieve that specificity of 98% and sensitivity of up to 
71% for intraoperative identification of metastases is 
useful and beneficial for avoiding a second operative 
procedure. The method can be improved by raising 
the quality of tissue used for imprint, the quality of 
imprint smears, and the quality of staining. In addi-
tion, the experience of cytologists and simultane-
ous intraoperative TIC analysis by two cytologists, 
although time consuming and involving more staff 
members, is likely to make this protocol even more 
accurate and reliable.
CONCLUSION
In our experience, touch imprint cytology assess-
ment of sentinel lymph nodes had 99% specificity 
and 57% sensitivity for intraoperative identification of 
melanoma metastasis, making it a useful and benefi-
cial tool for avoiding a second operative procedure.
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